Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases
Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases GlobeNewswire September 04, 2025 O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases Clinical Trial Application approval marks Onco3R's transition into a clinical-stage company Leuven, […]